Antagonism of mTOR Activity by a Kinetically Inert Rhodium(III) Complex

Bioactive Luminescent Transition-Metal Complexes for Biomedical Applications

(2013) Dik-Lung Ma et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors

(2013) Edward M. Wolin   CANCER LETTERS

Metal complexes as inhibitors of transcription factor activity

(2013) Chung-Hang Leung et al.   COORDINATION CHEMISTRY REVIEWS

Bioactive iridium and rhodium complexes as therapeutic agents

(2013) Chung-Hang Leung et al.   COORDINATION CHEMISTRY REVIEWS

Therapeutic Implications of mTOR Inhibitors in the Treatment of Gastric Cancer

(2013) Zhaode Bu et al.   CURRENT CANCER DRUG TARGETS

Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer

(2013) Xiaobei Zhang et al.   CURRENT CANCER DRUG TARGETS

Targeted delivery of platinum-based anticancer complexes

(2013) Jennifer S Butler et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Protein–protein interactions as druggable targets: recent technological advances

(2013) Alicia P Higueruelo et al.   CURRENT OPINION IN PHARMACOLOGY

Next-Generation Metal Anticancer Complexes: Multitargeting via Redox Modulation

(2013) Isolda Romero-Canelón et al.   INORGANIC CHEMISTRY

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

(2013) Valeria Azzarito et al.   Nature Chemistry

Enzyme inhibition by metal complexes: concepts, strategies and applications

(2013) Kelly J. Kilpin et al.   Chemical Science

Small-Molecule Stabilization of Protein-Protein Interactions: An Underestimated Concept in Drug Discovery?

(2012) Philipp Thiel et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

A Metal-Based Inhibitor of Tumor Necrosis Factor-α

(2012) Chung-Hang Leung et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Designing organometallic compounds for catalysis and therapy

(2012) Anna Louisa Noffke et al.   CHEMICAL COMMUNICATIONS

Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs

(2012) Wukun Liu et al.   CHEMICAL SOCIETY REVIEWS

Bioactive cyclometalated phthalimides: design, synthesis and kinase inhibition

(2012) Sebastian Blanck et al.   DALTON TRANSACTIONS

Pyridocarbazole-Rhodium(III) Complexes as Protein Kinase Inhibitors

(2012) Sandra Dieckmann et al.   EUROPEAN JOURNAL OF INORGANIC CHEMISTRY

High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction

(2012) Hacer Karatas et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

A Metal-Based Inhibitor of NEDD8-Activating Enzyme

(2012) Hai-Jing Zhong et al.   PLoS One

Structural biology and drug discovery for protein–protein interactions

(2012) Harry Jubb et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Inhibition of Janus kinase 2 by cyclometalated rhodium complexes

(2012) Chung-Hang Leung et al.   MedChemComm

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

(2011) R. Mallon et al.   CLINICAL CANCER RESEARCH

Metal-based antitumour drugs in the post-genomic era: what comes next?

(2011) Gianni Sava et al.   DALTON TRANSACTIONS

Targeting the mTOR kinase domain: the second generation of mTOR inhibitors

(2011) Yan-Jie Zhang et al.   DRUG DISCOVERY TODAY

Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer

(2011) Qingsong Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors

(2011) Sebastian Blanck et al.   ORGANOMETALLICS

Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β

(2010) G. Ekin Atilla-Gokcumen et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer

(2010) Qingsong Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor

(2010) Aranapakam M. Venkatesan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Organometallic Anticancer Compounds

(2010) Gilles Gasser et al.   JOURNAL OF MEDICINAL CHEMISTRY

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Targeting proteins with metal complexes

(2009) Eric Meggers   CHEMICAL COMMUNICATIONS

Inhibition of protein–protein interactions using designed molecules

(2009) Andrew J. Wilson   CHEMICAL SOCIETY REVIEWS

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

(2008) Sanjeev Shangary et al.   Annual Review of Pharmacology and Toxicology

Platinum(II) Complexes with Dipyridophenazine Ligands as Human Telomerase Inhibitors and Luminescent Probes for G-Quadruplex DNA

(2008) Dik-Lung Ma et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY